A Differential Response to Sunitinib: Sustained Systemic Response Paralleled by Intra-Dural Progression in the Spine. Should Standard Response Criteria Be Reviewed?

M Jafri, Emilio Porfiri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Orally available tyrosine kinases have revolutionized the treatment of renal cell carcinoma. These agents have impressive response rates compared with interferon and also have a cytostatic effect. We describe a case of a patient treated predominantly with continuous sunitinib who had a good partial response to sunitinib in the lungs, liver, adrenal gland, and lymph nodes but dural progression. We describe prolonged sustained response achieved by continuing sunitinib despite dural progression. This case demonstrates that standard treatment criteria may need reviewing.
Original languageEnglish
Pages (from-to)E42-E44
JournalClinical Genitourinary Cancer
Volume7
Issue number2
DOIs
Publication statusPublished - 1 Aug 2009

Keywords

  • Sciatica
  • Tyrosine kinases
  • Lower back pain

Fingerprint

Dive into the research topics of 'A Differential Response to Sunitinib: Sustained Systemic Response Paralleled by Intra-Dural Progression in the Spine. Should Standard Response Criteria Be Reviewed?'. Together they form a unique fingerprint.

Cite this